-+ 0.00%
-+ 0.00%
-+ 0.00%
Xinhua Pharma wins China approval for magnesium, sodium and potassium sulfate oral solution
Share
Listen to the news
Xinhua Pharma wins China approval for magnesium, sodium and potassium sulfate oral solution
  • Shandong Xinhua Pharmaceutical won China NMPA drug registration for a magnesium sulfate, sodium sulfate, potassium sulfate oral solution.
  • Product targets adult bowel cleansing ahead of procedures requiring intestinal visualization.
  • Listed in China’s 2025 basic medical insurance catalogue as Category B; 2025 public-hospital sales reached about RMB 490 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shandong Xinhua Pharmaceutical Company Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260918-12337564), on September 18, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending